Momenta Pharmaceuticals (NASDAQ:MNTA) Receives Daily News Sentiment Score of 0.28

Media headlines about Momenta Pharmaceuticals (NASDAQ:MNTA) have trended positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Momenta Pharmaceuticals earned a coverage optimism score of 0.28 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 44.5704719193529 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news articles that may have impacted Accern’s analysis:

Shares of NASDAQ:MNTA traded up $0.35 during mid-day trading on Thursday, hitting $18.15. The stock had a trading volume of 857,489 shares, compared to its average volume of 916,325. The firm has a market cap of $1,325.81, a price-to-earnings ratio of -14.88 and a beta of 1.72. Momenta Pharmaceuticals has a fifty-two week low of $11.85 and a fifty-two week high of $19.25.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.12. Momenta Pharmaceuticals had a negative return on equity of 23.62% and a negative net margin of 63.43%. The business had revenue of $64.60 million for the quarter, compared to the consensus estimate of $66.59 million. During the same quarter last year, the business posted $0.60 EPS. The business’s revenue was up 88.9% on a year-over-year basis. sell-side analysts forecast that Momenta Pharmaceuticals will post -1.27 EPS for the current year.

MNTA has been the topic of several recent analyst reports. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. ValuEngine upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 23rd. BidaskClub downgraded Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, Stifel Nicolaus restated a “hold” rating and issued a $18.00 price objective on shares of Momenta Pharmaceuticals in a report on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $15.33.

In related news, CEO Craig A. Wheeler sold 3,938 shares of Momenta Pharmaceuticals stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $16.46, for a total value of $64,819.48. Following the transaction, the chief executive officer now directly owns 239,869 shares in the company, valued at approximately $3,948,243.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Craig A. Wheeler sold 35,666 shares of Momenta Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $14.11, for a total value of $503,247.26. The disclosure for this sale can be found here. Insiders sold a total of 106,502 shares of company stock worth $1,661,696 in the last three months. Company insiders own 4.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Momenta Pharmaceuticals (NASDAQ:MNTA) Receives Daily News Sentiment Score of 0.28” was first posted by BBNS and is the property of of BBNS. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://baseballnewssource.com/2018/03/29/momenta-pharmaceuticals-mnta-earns-daily-media-impact-score-of-0-28/1971626.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings


Leave a Reply

 
© 2006-2018 BBNS.